Last reviewed · How we verify
Express Specialty Pharmacy — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
12 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Prilocaine 2.5% | Prilocaine 2.5% | marketed | Local anesthetic (amide) | Voltage-gated sodium channels | Anesthesia |
Therapeutic area mix
- Anesthesia · 1
- Anesthesiology · 1
- Musculoskeletal/Pain Management · 1
- Oncology · 1
- Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Nantes University Hospital · 3 shared drug classes
- Oslo University Hospital · 2 shared drug classes
- Bozyaka Training and Research Hospital · 2 shared drug classes
- Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias · 2 shared drug classes
- Keimyung University Dongsan Medical Center · 2 shared drug classes
- Kasr El Aini Hospital · 2 shared drug classes
- Beijing Tiantan Hospital · 2 shared drug classes
- Pontificia Universidad Catolica de Chile · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Express Specialty Pharmacy:
- Express Specialty Pharmacy pipeline updates — RSS
- Express Specialty Pharmacy pipeline updates — Atom
- Express Specialty Pharmacy pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Express Specialty Pharmacy — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/express-specialty-pharmacy. Accessed 2026-05-14.